|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Abbott Laboratories (ABT)' Device, Dx Biz Poised for Growth After Spin-Out Finalizes; Analysts
9/21/2012 9:02:03 AM
Analysts on Wall Street are divided in their assessments of Abbott's prospects after it spins out its branded pharmaceuticals business. Wall Street analysts are by and large predicting good things for Abbott (NYSE:ABT) after it spins out its branded pharmaceuticals division, to be named AbbVie, early next year. But, although some are decidedly bullish on ABT, others are taking a more cautious approach until more is known about the structure of the deal. Jeffrey Holford, an analyst for Jefferies & Co., boosted his price target on the stock from $75 to $85 this week, telling investors that post-split Abbott is poised for "exceptional growth," according to The Associated Press. Abbott is Holford's top pick for the rest of the year, rated at "buy," the news service reported.
|
|
|
|
|
|
|
|
|
|
|